| Name | Title | Contact Details |
|---|
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.
VintaBio is a life sciences company that specializes in customized process development, GMP manufacturing, and quality control services for cell and gene therapies.
For pharmaceutical manufacturers and healthcare providers, AmerisourceBergen Specialty Group is an essential business partner.
Merck-Medco is a Franklin Lakes, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.